Interferon beta (IFN-beta)

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S3647
R7580
Nguyen (control exposed to Glatiramer), 2019 Pre-term (<37 weeks) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.81 [0.47;1.40] C
excluded (control group)
57/268   24/96 81 268
ref
S3648
R7583
Nguyen (control unexposed, sick), 2019 Pre-term (<37 weeks) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 0.75 [0.53;1.05] C 57/268   182/686 239 268
ref
S3716
R7991
Thiel (control unexposed, sick), 2016 Preterm birth early pregnancy prospective cohort unexposed, sick Adjustment: Yes 0.64 [0.30;1.37] 15/227   18/181 33 227
ref
S3632
R7438
Fragoso a (control exposed to Glatiramer), 2013 Prematurity (NOS) during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick excluded Adjustment: No 6.91 [0.79;60.38] C
excluded (control group)
6/39   1/39 7 39
ref
S3633
R7454
Fragoso a (control unexposed, sick), 2013 Prematurity (NOS) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 5.58 [1.32;23.58] C 6/39   3/95 9 39
ref
S3636
R7513
Fragoso b (control exposed to Glatiramer), 2013 Premature delivery at least 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.80 [0.03;20.62] C
excluded (control group)
0/17   1/41 1 17
ref
S3637
R7529
Fragoso b (control unexposed, sick), 2013 Premature delivery at least 1st trimester retrospective cohort unexposed, sick Adjustment: No 1.77 [0.07;45.30] C 0/17   1/89 1 17
ref
S3643
R7562
Giannini (control exposed to Glatiramer), 2012 Preterm delivery (NOS) early pregnancy prospective cohort exposed to other treatment, sick excluded Adjustment: No 1.47 [0.43;5.02] C
excluded (control group)
25/76   4/16 29 76
ref
S3644
R7567
Giannini (control unexposed, sick), 2012 Preterm delivery (NOS) early pregnancy prospective cohort unexposed, sick Adjustment: Yes 2.11 [1.18;3.78] 25/76   58/288 83 76
ref
S3613
R7360
Weber-Schoendorfer (control exposed to Glatiramer), 2009 Preterm births at least 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 3.06 [0.35;26.93] C
excluded (control group)
6/53   1/25 7 53
ref
S3614
R7364
Weber-Schoendorfer (control unexposed, disease free), 2009 Preterm births at least 1st trimester prospective cohort unexposed, disease free excluded Adjustment: No 1.85 [0.62;4.44]
excluded (control group)
6/53   90/1,377 96 53
ref
S3615
R7368
Weber-Schoendorfer (control unexposed, sick), 2009 Preterm births at least 1st trimester prospective cohort unexposed, sick Adjustment: No 0.75 [0.24;2.33] C 6/53   8/55 14 53
ref
S3723
R8019
Boskovic (control unexposed, disease free), 2005 Preterm birth (< 37 weeks gestation (postconception). 1st trimester prospective cohort unexposed, disease free excluded Adjustment: No 1.81 [0.15;21.60] C
excluded (control group)
2/23   1/20 3 23
ref
S3724
R8024
Boskovic (control unexposed, sick), 2005 Preterm birth (< 37 weeks gestation (postconception). 1st trimester prospective cohort unexposed, sick Adjustment: No 0.57 [0.09;3.81] C 2/23   3/21 5 23
ref
Total 7 studies 1.12 [0.63;1.99] 384 703
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Nguyen (control unexposed, sick), 2019Nguyen, 2019 1 0.75[0.53; 1.05]23926826%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Thiel (control unexposed, sick), 2016Thiel, 2016 2 0.64[0.30; 1.37]3322719%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Fragoso a (control unexposed, sick), 2013Fragoso a, 2013 3 5.58[1.32; 23.58]93910%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Fragoso b (control unexposed, sick), 2013Fragoso b, 2013 4 1.77[0.07; 45.30]1173%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Giannini (control unexposed, sick), 2012Giannini, 2012 5 2.11[1.18; 3.78]837622%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Weber-Schoendorfer (control unexposed, sick), 2009Weber-Schoendorfer, 2009 6 0.75[0.24; 2.33]145313%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Boskovic (control unexposed, sick), 2005Boskovic, 2005 7 0.57[0.09; 3.81]5237%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (7 studies) I2 = 64% 1.12[0.63; 1.99]3847030.220.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: control unexposed, sick; 2: control unexposed, sick; 3: control unexposed, sick; 4: control unexposed, sick; 5: control unexposed, sick; 6: control unexposed, sick; 7: control unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.12[0.63; 1.99]38470364%NANguyen (control unexposed, sick), 2019 Thiel (control unexposed, sick), 2016 Fragoso a (control unexposed, sick), 2013 Fragoso b (control unexposed, sick), 2013 Giannini (control unexposed, sick), 2012 Weber-Schoendorfer (control unexposed, sick), 2009 Boskovic (control unexposed, sick), 2005 7 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.12[0.63; 1.99]38470364%NANguyen (control unexposed, sick), 2019 Thiel (control unexposed, sick), 2016 Fragoso a (control unexposed, sick), 2013 Fragoso b (control unexposed, sick), 2013 Giannini (control unexposed, sick), 2012 Weber-Schoendorfer (control unexposed, sick), 2009 Boskovic (control unexposed, sick), 2005 7 Tags Adjustment   - No  - No 1.07[0.50; 2.26]26840046%NANguyen (control unexposed, sick), 2019 Fragoso a (control unexposed, sick), 2013 Fragoso b (control unexposed, sick), 2013 Weber-Schoendorfer (control unexposed, sick), 2009 Boskovic (control unexposed, sick), 2005 5   - Yes  - Yes 1.19[0.37; 3.83]11630383%NAThiel (control unexposed, sick), 2016 Giannini (control unexposed, sick), 2012 2 All studiesAll studies 1.12[0.63; 1.99]38470364%NANguyen (control unexposed, sick), 2019 Thiel (control unexposed, sick), 2016 Fragoso a (control unexposed, sick), 2013 Fragoso b (control unexposed, sick), 2013 Giannini (control unexposed, sick), 2012 Weber-Schoendorfer (control unexposed, sick), 2009 Boskovic (control unexposed, sick), 2005 70.220.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.94.01.9860.000Nguyen (control unexposed, sick), 2019Thiel (control unexposed, sick), 2016Fragoso a (control unexposed, sick), 2013Fragoso b (control unexposed, sick), 2013Giannini (control unexposed, sick), 2012Weber-Schoendorfer (control unexposed, sick), 2009Boskovic (control unexposed, sick), 2005

Asymetry test p-value = 0.4912 (by Egger's regression)

slope=-0.2802 (0.3948); intercept=0.8429 (1.1353); t=0.7424; p=0.4912

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 3723, 3613, 3614, 3643, 3632, 3636, 3647

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.84[0.74; 4.60]99760%NAWeber-Schoendorfer (control unexposed, disease free), 2009 Boskovic (control unexposed, disease free), 2005 2 unexposed, sick controlsunexposed, sick controls 1.12[0.63; 1.99]38470364%NANguyen (control unexposed, sick), 2019 Thiel (control unexposed, sick), 2016 Fragoso a (control unexposed, sick), 2013 Fragoso b (control unexposed, sick), 2013 Giannini (control unexposed, sick), 2012 Weber-Schoendorfer (control unexposed, sick), 2009 Boskovic (control unexposed, sick), 2005 7 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.26[0.64; 2.47]12545320%NANguyen (control exposed to Glatiramer), 2019 Fragoso a (control exposed to Glatiramer), 2013 Fragoso b (control exposed to Glatiramer), 2013 Giannini (control exposed to Glatiramer), 2012 Weber-Schoendorfer (control exposed to Glatiramer), 2009 50.510.01.0